Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) is extending the review timeline of the supplemental New Drug Application (sNDA) for Invokana (canagliflozin; Janssen) by 3 months in order to have extra time to review additional data related to the reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus.
The sNDA includes data from the Phase 3 CANVAS program which showed that the sodium-glucose co-transporter 2 (SGLT2) inhibitor reduced the combined risk of cardiovascular death, myocardial infarction, and nonfatal stroke in patients with type 2 diabetes. The application also includes the fixed-dose combinations, Invokamet (canagliflozin, metformin tablets) and Invokamet XR (canagliflozin, metformin extended-release tablets).
The FDA has set a new action date of October 2018 for this indication.
Invokana is currently approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
For more information visit Janssen.com.
